Hepatitis C
EASL 2016: Sofosbuvir, Velpatasvir, and GS-9857 Works Well for Treatment-Experienced HCV Patients
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 14 April 2016 00:00
A triple combination of Gilead Sciences' sofosbuvir, velpatasvir, and GS-9857 demonstrated a high sustained response rate for treatment-experienced people with all hepatitis C virus (HCV) genotypes who previously were not cured with prior direct-acting antivirals (DAAs), according to 2 presentations at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this week in Barcelona.
EASL 2016: International Liver Congress Underway this Week in Barcelona
- Details
- Category: HCV Treatment
- Published on Wednesday, 13 April 2016 00:00
The European Association for the Study of the Liver's International Liver Congress (EASL 2016) takes place April 13-17 at Fira de Barcelona. The Congress is one of the key annual scientific meetings covering hepatitis B and C and its complications, as well as other liver diseases. HIVandHepatitis.com and our partners at Aidsmap will be providing on-site coverage starting Thursday, April 14.
Hepatitis C Epidemic in North America Peaked Between 1940 and 1965
- Details
- Category: HCV Epidemiology & Mortality
- Published on Wednesday, 06 April 2016 00:00
The spread of hepatitis C virus (HCV) in North America peaked between 1940 and 1965, according to research published in the March 30 advance edition of Lancet Infectious Diseases. The investigators attribute the rapid spread of the infection to hospital transmissions and reuse of medical injection equipment rather than risky behaviors such as injection drugs, unsafe tattooing, and unprotected sex.
Hepatitis B and C Transmission Could Be Ended in the U.S., Report Says
- Details
- Category: Hepatitis B
- Published on Tuesday, 12 April 2016 00:00
Hepatitis B and C could be eliminated as a public health threat in the U.S. by treating more people in order to end transmission and prevent progression of liver disease and death, according to a new report from the National Academies of Sciences, Engineering, and Medicine (formerly the Institute of Medicine).
U.S. Government Releases New Guidance for Syringe Program Funding
- Details
- Category: Injection Drug Use
- Published on Wednesday, 06 April 2016 00:00
The U.S. Department of Health and Human Services (DHHS) has released new guidance regarding use of federal funds to pay for many aspects of syringe service programs aimed at reducing the risk of HIV and viral hepatitis transmission among people who inject drugs. The guidance follows a change in federal law that lifts the overall ban on syringe service funding, although the new rules do not allow programs to pay for needles or syringes themselves.
CROI 2016: Hepatitis C [VIDEO]
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 April 2016 00:00
New interferon-free treatment for hepatitis C virus (HCV) has brought about a revolution in treatment, but challenges still remain -- among them too few people with HCV being diagnosed and the high cost of the new drugs -- before the mission can be declared a success. A panel of hepatitis C experts discuss research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections(CROI) in Seattle with HIVandHepatitis.com editor Liz Highleyman in this IFARA video.
CROI 2016: Primary Care Providers Can Successfully Treat People with Hepatitis C
- Details
- Category: HCV Treatment
- Published on Thursday, 31 March 2016 00:00
Direct-acting antiviral therapy for hepatitis C delivered by non-specialists such as primary care physicians and nurse practitioners is safe and effective -- even for the most difficult-to-treat patients -- and could potentially help increase the number of people receiving treatment, according to findings from the ASCEND study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last month in Boston.
CROI 2016: Advances in Hepatitis C Research [VIDEO]
- Details
- Category: HCV Treatment
- Published on Wednesday, 06 April 2016 00:00
Interferon-free therapy can now cure most patients with chronic hepatitis C, but challenges still remain, including persistent liver damage and cancer risk and HCV reinfection after successful treatment. A panel of hepatitis C experts discuss research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) and related news with HIVandHepatitis.com editor Liz Highleyman in this IFARA video update.
CROI 2016: Ravidasvir Plus Sofosbuvir Demonstrates High Cure Rate for HCV Genotype 4
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 04 March 2016 00:00
Sofosbuvir plus the investigational HCV NS5A inhibitor ravidasvir, with or without ribavirin, cured 95% to 100% of people with hepatitis C virus (HCV) genotype 4, the most common type in Egypt, according to findings from the Pyramid 1 study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last week in Boston.
More Articles...
- CROI 2016: Harvoni for 6 Weeks Cures HIV+ People with Acute HCV if Viral Load is Low
- Daclatasvir Plus Asunaprevir Cures Most Genotype 1b Chinese Hepatitis C Patients
- Direct-Acting Antivirals Reduce Cryoglobulinemia in People with Hepatitis C
- AASLD 2015: Sofosbuvir Plus Ribavirin Shows Suboptimal Efficacy for Acute Hepatitis C
- FDA Approves Harvoni for Hepatitis C Patients with Advanced Liver Disease
Web Design and Development by